Biovest is to separate its instrument and contract manufacturing offerings into a single subsidiary, Cell Culture Company, which will focus on bioreactors and bioservice solutions
Cell Culture will supply automated single-use perfusion bioreactor systems and custom mammalian cell and protein manufacturing services to the diagnostic, therapeutic and animal healthcare industries.
Cell Culture president, Christiaan Engstrom, said: “The spin-off of Cell Culture Company will ensure that our instrument and CMO customers will be better served through increased focus and investment.”
Biovest will continue to commercialise personalised immunotherapies and deliver GMP custom mammalian cell and protein production and service solutions, according to the company.
Engstrom said: “It is our goal to be recognised as a preferred partner and industry leader in bioreactor technology and cell culture services.”
Cell Culture will remain located in the Minneapolis, Minnesota area. The location is home to the corporate offices, bioreactor manufacturing operations and a distribution center, as well as an FDA-compliant custom mammalian and protein production laboratory.